- Record: found
- Abstract: found
- Article: not found
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Roger Stupp
1 ,
Monika E Hegi ,
Warren P Mason ,
Martin J van den Bent ,
Martin J B Taphoorn ,
Robert C Janzer ,
Samuel K Ludwin ,
Anouk Allgeier ,
Barbara Fisher ,
Karl Belanger ,
Peter Hau ,
Alba A Brandes ,
Johanna Gijtenbeek ,
Christine Marosi ,
Charles J Vecht ,
Karima Mokhtari ,
Pieter Wesseling ,
Salvador Villa ,
Elizabeth Eisenhauer ,
Thierry Gorlia ,
Michael Weller ,
Denis Lacombe ,
J Gregory Cairncross ,
René-Olivier Mirimanoff
May 2009
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
In 2004, a randomised phase III trial by the European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trials Group (NCIC) reported improved median and 2-year survival for patients with glioblastoma treated with concomitant and adjuvant temozolomide and radiotherapy. We report the final results with a median follow-up of more than 5 years.